~~<i id='D02F5883F2'><strike id='D02F5883F2'><tt id='D02F5883F2'><pre id='D02F5883F2'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：Wikipedia 2025-10-06 13:36:59 Page View：9892

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DeepMind touts AlphaFold's new skills as protein folding AI models face off
Next article： Activists slam private health insurers over coverage restrictions

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

FDA panel signals lack of confidence in Amgen cancer drug data

AdobeTheclearanceofafirst-of-its-kindcancertreatmentmadebyAmgenisonshakiergroundfollowingaFoodandDru

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

FDA authorizes Novavax’s updated Covid

NICOLASMAETERLINCK/BELGAMAG/AFPviaGettyImagesTheFoodandDrugAdministrationonTuesdayauthorizedNovavax’